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The Protective Role of Folic Acid and Vitamin E Against  Toxical Effects of 
Valproic Acid on Liver Tissue During Period of Gestation 
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SUMMARY 
Valproic acid is an anticonvulsan drug used in epilepsy. The 
histopathological changes of valproic acid on liver and  the protective effect 
of vitamin E and also folic acid were observed. 24 adult female Wistar Albino 
rats were used. The first control,  the second valproic acid group that was 
given 300 mg/kg on 8.9. and 10. days of gestation, the third valproic acid 
+vitamin E group. Vitamin E was given 250mg/kg via nasogastric intubation 
before one hour  administration of valproic acid on 8.9.10.days of gestation. 
The fourth valproic acid+ folic acid group; via valproic acid, folic acid was 
given  400 microgram ordinarily in drinking water per day. In the liver 
sections of valproic acid group, perivenullar dilatation, swelling of Kuppfer 
cells, microvesicular steatosis and degeneration were observed. In the second 
group there was  moderate degeneration in hepatocytes,necrotic areas in 
some places, mononuclear cell infiltration. In valproic acid +vitamin E group 
normal-like appearance of the structure of Remark cell lines were observed. 
Under these source of results, we  viewed antioxidants decreased the 
hepatotoxicity on liver tissue by using folic acid and vitamin E . 
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Gebelik Sürecinde Valproik Asit’in Karaciğer Dokusundaki Toksik Etkilerine 
Karşı Folik Asit ve Vitamin E’nin Koruyucu Rolü 
ÖZET 
Valproik asit epilepside kullanılan antikonvülzan bir ilaçtır. Valproik 
Asit’in karaciğer üzerinde yaptığı histopatolojik değişiklikler ile folik asit ve 
vitamin E’nin koruyucu etkileri incelendi. 24 erişkin dişi Wistar Albino tipi 
sıçan kullanıldı. Birinci grup kontrol, ikinci grup gebeliğin 8.9. ve 10. 
günlerinde 300mg/kg dozunda valproik asit verilen grup, üçüncü grup 
valproik asit+vitamin E grubuydu. Vitamin E, valproik asit uygulamasından 
bir saat önce 250mg/kg dozunda nazogastrik intübasyonla yine gebeliğin 
8.9.10.günlerinde verildi. Dördüncü valproik asit+folik asit grubuna valproik 
asit yanında, içme suyuna düzenli olarak her gün  400 mikrogram dozunda 
folik asit katıldı. Valproik asit grubunun karaciğer kesitlerinde perivenüller 
dilatasyon, Kuppfer hücre şişmesi, mikroveziküler steatozis ve dejenerasyon 
izlendi. Üçüncü grubun hepatositlerinde orta derecede dejenerasyon, bazı 
yerlerde nekrotik alanlar ve mononükleer hücre infiltrasyonu görüldü. 
Dördüncü grupta Remark hücre kordonlarının görünümü normale yakındı. 
Bu bulguların  ışığı altında folik asit ve vitamin E kullanarak 
antioksidanların hepatotoksisiteyi azalttığını izledik. 
Anahtar Kelimeler: Karaciğer, Valproik Asit, Folik Asit, Vitamin E, 
Hepatotoksisite  
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INTRODUCTION 
Valproic acid (VPA), an eight carbon 
branched chain fatty acid with a broad 
spectrum of anticonvulsant activity, is used in 
the treatment of epilepsy. (1,2) This structure 
may enable VPA to interact with cell 
membranes, which may account in part for 
both its therapeutic and adverse effects (3 ). 
As early as 1979 and 1980, the first case 
reports of valproate (VPA) induced hepatic 
failure were published (4,5). The increased 
clinical use of valproate has been accompanied 
by reports of hepatic dysfunction and renal 
tubular defects (6,7). 
Valproic acid, introduced as an 
anticonvulsant in Europe in 1968 and in the 
United States in 1978, and given to 200.000 
new patients annually, has been associated 
rarely with fulminant fatal hepatitis (8,9). 
Valproate toxicity is thought to be 
idiosyncratic and metebolic without an 
immunologic basis (8,10). 
Valproic acid, a frequently used drug for 
the treatment of epilepsy, has been used 
worldwide (I) However, valproic acid therapy 
is responsible for a number of fatal cases of 
hepatic failure (11, 12). Hence the mechanism 
by which valproic acid causes hepatotoxicity is 
poorly understood (13 ). 
VPA, a widely used anticonvulsant drug, 
induced the deterioration of trace metal 
homeostasis, including zinc (Zn) deficiency in 
experimental animals (14,15). 
As clinical usage of VPA increased, reports 
of its hepatotoxicity began to appear. This 
toxicity ranges from mildly increased 
aminotranspherase enzymes in 15 to 30 percent 
of patients to liver failures (16) and death in 
some patients (17). 
Two types of serious side-effects are 
associated with the use of VPA: hepatotoxicity 
and teratogenicity (7). This teratogenitic 
effects includes neural tube defects in human 
and experimental animals (18,19,20). The 
toxicity is apparently due to metabolites of 
VPA generated by w- oxidation, (21) which is 
one of three major metabolic pathways of VPA 
biotransformation (22,23). This is a 
cytochrome P-450 mediated reactin occuring  
 
 
in the microsomes and as such may be induced 
or inhibited by various agents (3). It normally 
accounts for 10 to 15 percent of VPA 
metabolism (22,23) but within the hepatocyte 
system it can be induced to enhance toxicity or 
inhibited to decrease toxicity (24). 
MATERIALS and METHODS 
In this study, 24 adult female Wistar-
Albino rats weighing 200 to 250 gr.,  obtained 
from Experimental Research Institute of Dicle 
University (DÜSAM) were used. The female 
rats coupled with male rats and on the other 
morning examined for cervical plug. The 
female rats with positive cervical plug were 
accepted having gestation. The female rats 
randomly assigned to  four groups. All groups 
were given standart laboratory chow and tap 
water. The first group was the control group 
fed standart laboratory chow and tap water.   
The second group injected VPA. VPA 
(Valproic acid; Na valproate Sigma P 4543) 
was given 300 mg/kg after diluation with 
saline solution on 8, 9 and 10
th days of 
gestation via subcutan injection in loose 
connective tissue of the right leg.  The third 
group was VPA and Vit. E group. Vit E was 
given 250mg/kg by  diluating olive oil via 
nasogastric intubation, whereas VPA was 
given 300 mg/kg. before one our   
administration of Vit E (Vitamin E, α-
Tocopherol, Sigma  T-3251) on 8, 9 and 10
th 
days of gestation. The fourth group was VPA 
and FA group. VPA was given 300 mg/kg also 
on 8.9. and 10.days of gestation and FA ( Folic 
Acid, Pteryoglutamic acid vit M, Sigma F 
8798) was given  400 microgram ordinarily in 
drinking water per day during pregnancy. On 
the 20
th day of gestation female rats were 
sacrified. The liver was removed from each 
goup and fixed neutral buffered formalin 
solution for 24 h., some of these samples were 
fixed in bouin solution. The paraffine sections 
of the biopcies were cut approximately 5µm in 
thickness. These sections were histochemically 
stained with Hematoxylen-Eosine (H&E) and 
Periodic Acide Shiff (PAS). Microphotographs 
were being taked after the microscopic 
examination of stained sections.   
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RESULTS 
In the slides of liver sections of the control 
group stained with Hematoxylene-Eosine, the 
appearanc of the liver was histologically 
normal (Figure 1a). 
Figure 1 a. (Control group)  normal liver 
appearance.  
In the slides of liver sections of valproic 
acid group stained with Hematoxylene-Eosine; 
perivenullar dilatation, swelling of Kuppfer 
cells, microvesicular steatosis and 
degeneration in acidophilic structures of 
hepatocytes were observed. In another liver 
section of the same group, degeneration and 
inflammation at the periportal zone, 
mononuclear cell infiltration, necrotic areas 
and picnosis, affected liver homogenity, 
reactive and degenerative alterations in 
hepatocytes were also observed (Figure 1b).  
Figure 1  b.  (VPA group)  Perivenullar 
Dilatation (→), Swelling in Kupffer cells (►)  
Microvesicular Steatosis (*),Acidophilic 
degeneration in some areas of hepatocytes 
(A),Periportal Degeneration (PD), 
Mononuclear cell infiltration (Mİ),  Picnosis 
(PN). (H.E.Originalmagnification X 82). 
In the sections stained with PAS, 
heterogenity in the distribution of glycogen, 
dens mononuclear cell infiltrations at 
periportal zone, particularly arround the V.  
 
hepatica interlobularis, were observed. In 
addition, swelling in Kuppfer cells, 
perivenullar dilatation, degeneration in 
hepatocytes, decreasing in the clarity of classic  
liver-lobule construction, multivesicular 
steatosis at some area were examined (Figure2). 
Figure 2. (VPA group)  Heterogenity in 
distrubution of glycogen  (GH), Mononuclear 
cell infiltration around V. Hepatica 
İnterlobularis (Mİ), Swelling in Kupffer 
cells(►),Perivenullar Dilatation (→),Piknosis 
(PN), Microvesicular Steatosis (*),Congestion 
in V. Porta İnterlobularis (VK). (PAS, Original 
magnification X82). 
Degeneration in hepatocytes associated 
with progress on to pycnosis and necrosis, 
degeneration and congestion in V.hepatica 
interlobularis at periportal zone, increasing in 
connective tissue, infiltration and oedema in 
periportal zone were observed (Figure 3). 
Figure 3. (VPA+FA group)  Congestion in 
interlobular veins at perportal area(VK), 
Periportal Mononuclear cell infiltration (Mİ), 
Very few degeneration in the structure of 
Remark cell lines (R ), Picnosis in some areas 
of hepatocytes (PN), Swelling in Kupffer cells 
(►), Microvesicular  Steatosis (*),Perivenullar 
Dilatation (→) (H.E. Original magnification 
X82)   
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In the liver sections stained with 
Hematoxylene-Eosine, congestion in arteries 
and veins at periportal zones, inflammation at 
moderate grade, mononuclear cell infiltration, 
mild degeneration in the construction of 
Remark cell lines, pycnosis at some areas of 
hepatocytes, swelling of Kuppfer cells, 
congestion in V.centralis, increasing in 
vascularization, dilatation in perivenullar 
sinuzoides, severe decrease in microvesicular 
steatosis were examined (Figure 3). 
In the liver sections stained with PAS, 
heterogenity at the distribution of glycogen in 
hepatocyte cytoplasm, mononuclear cell 
infiltration in periportal zone and swelling of 
Kuppfer cells were seen. 
Mild congestion in V. centralis, moderate 
degeneration in hepatocytes,necrotic areas in 
some places,mild degeneration in the 
construction of Remark cell lines, 
monocellular infiltration, mild increase in 
connective tissue were observed (Fig 4). 
Figure 4.  (VPA+FA group)  Heterogenity in 
distrubition of glycogen(GH),  Mononuclear cell 
infiltration in periportal area  (Mİ), Swelling in 
Kupffer cells (►), Mononuclear cell infiltration in 
some areas of liver parenchyme near V.centralis 
(Mİ),  Necrotic areas in some areas of hepatocytes 
(NA).(PAS, Original magnification X82). 
 
In the liver sections stained with 
Hematoxylene-Eosine,mild congestion in 
V.centralis, we observed mild degeneration in 
the construction of Remark cell lines and 
dilatation at some perivenullar sinuzoides, mild 
swelling in Kuppfer cells,normal-like 
appearance of hepatocytes, no microvesicular 
steasosis congestion in arteries and veins in 
periportal zone, mild infiltration of 
mononuclear cells.(Fig 5,6) 
In the liver sections stained with PAS, 
nearly normal-like appearance of V.centralis, 
very mild microvesicular steatosis, mild 
dilatation in perivenullar sinuzoides,normal-
like appearance of the structure of hepatocytes 
and mild heterogenity in their distribution of 
glycogen, swelling and hyperplasia in Kuppfer 
cells, mild degree of mononuclear cell 
infiltration in periportal zone were seen. 
Mild degeneration in hepatocytes and 
dilatation in some sinuzoides, mild congestion 
in V.centralis, normal-like appearance of the 
structure of Remark cell lines, and periportal 
zone, and mild increase in connective tissue 
were observed (Fig.5, 6). 
Figure 5.  (VPA+Vit E group) İncreasing rate of 
congestion in V.Centralis (VK),  Few degeneration 
in the structure of Remark cell lines (R ), Dilatation 
in some areas of perivenullar sinuzoides  (→), A 
few swelling in Kupffer cells (►),The appearance 
of hepatocytes nearly normal (H), Microvesicular 
Steatosis is almost non present ( *),The grade of 
mononuclear cell infiltration is little in periportal 
area  (Mİ) .(H.E. Original magnification X82). 
Figure 6. (VPA+Vit E group) Moderate 
congestion in V.Centralis (VK), 
Microvesicular Steatosis is very few (*), Little 
dilatation in perivenullar sinuzoides (→), Little 
heterogenity in the glycogen structure of 
hepatocytes (GH), Little mononuclear cell 
infiltration in periportal area (Mİ),  Kuppfer 
cell hipertophy +hiperplasia (KH). (PAS, 
Original magnification X82).   
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DISCUSSION  
The mechanism by which VPA causes 
hepatic damage is uncertain; hepatotoxicity is 
suspected to result from the formation of toxic 
VPA metabolites (25,26,27,28) or altered 
antioxidant enzyme activities (29). 
Published reports on valproate-induced 
hepatotoxicity and renal tubular disorder 
provide sufficient information on the 
pathological changes induced in these cells. 
However, none of them has described these 
changes as a function of time of exposure (30). 
But liver biopsy on some patients taking 
valproate therapy indicated hepatic necrosis, 
hepatitis, centerlobular necrosis, cirrhosis, 
hepatomegaly with fatty infiltration, 
cholestasis and inflamation, as well as end-
stage liver disease, with multinodular changes 
and fibrosis (31). However, the information on 
these cases is scantly and variable.  
As we worked only with liver biopcies in 
our study,  we determined that the findings we 
viewed that the histopathological changes of 
VPA on liver were similar at large rate with 
the studies of Jeavons P.M.et al (1982) almost 
Quereshi and his friends hadn’t determined 
before. 
Pathomorphological changes in mouse 
liver and kidney during prolonged valproate 
administration  (30). 
Most studies on hepatic disorder report 
microvesicular steatosis in periportal regions 
of the liver lobule after a single dose of 
valproate (32,33). Our study was paralel with 
the results of Kochen, Siemens and Graf 
(28,29).  
Folic acid is converted, in the precence of 
ascorbic acid, in the liver and plasma to its 
metabolic active form (tetrahydrofolic  acid) 
by dihydrofolate reductase. A large proportion 
of the biotransformation is hepatic. Folate 
deficiency can be linked to scurvy (34,35). 
The action of folic acid on the regenerative 
response in the liver has not yet been 
elucidated (36), however it is not known 
whether folic acid can inhibit cell proliferation. 
In the study of M. Komatsu and friends, 
they couldn’t explained whatever if folic acid 
has regenerative changes on liver and whether 
folic acid inhibits the cell proliferation.  
 
Although we viewed that there has been 
proliferation and regeneration almost little on 
the cells of hepatocytes and Kuppfer cells of 
the liver according to the effect of folic acid. 
Accompanying with these results we 
determined the proliferative and regenerative 
effects of folic acid on the liver which 
M.Komatsu and friends hadn’t explained 
before (36). 
The present concessus, therefore, is that 
diet low in methionin and devoid of choline 
and folate are sufficient to independently 
induce tumor formation in rats, primarly in the 
liver (37).  
As we also observed the presence of 
pycnotic and necrotic areas which VPA had 
made because of the absence of folic acid in 
the VPA group, even there was almost no 
necrotic areas and there was a decrease in 
pycnosis in VPA+FA group. As it had a 
supporting quality in the study which   
Lombardi and friends had made via the level of 
light microscopy.  
Chronic treatment with VPA has been 
shown to decrease the levels of antioxidants 
such as vitamin E and glutathion  peroxidase 
further suggesting the role of oxidative stres . 
Moreover, recent studies have shown 
protective effect of vitamin C and vitamin E 
against VPA induced hepatotoxicity (7 ).  
We didn’t explored the results even if   
VPA decreased the realing of antioxidants 
which Juriva-Romet M.et al (1996) mentioned 
hence we examined the effects of folic acid 
and Vitamin E on liver hepatotoxicity instead 
of Vitamin E and glutathion peroxidase which 
had been mentioned. Almost together it was 
clarified that Vitamin E and C decreased 
hepatotoxicity that Juriva-Romet M. et al 
(1996) mentioned in their literatur. Under these 
source of results we also viewed  by using folic 
acid and vitamin E of which are antioxidants 
decreased the hepatotoxicity on liver tissue. 
We determined that our study was paralel with 
the results of Juriva-Romet M.et al (1996) 
which they had recorded that the antioxidants 
decrease the liver hepatotoxicity. 
The present study examines the effect of 
such known free-radical scarengers, vitamin E   
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on sodium valproate toxicity in the rat 
hepatocyte model. These scavengers would be 
expected to reduce any free radical 
metabolities and thus prevent lipid 
peroxidation and toxicity.The decrease in 
toxicity could simply be a consequence of Vit 
E stabilizing the hepatocyte membrans, 
allowing less lactate dehydrogenase (LDH) to 
be released into the surrounding media and 
thus decreasing the LDH index (3). 
We couldn’t obtained the amount of LDH 
biochemically in our study. But we determined 
that the finding vesicular steatosis was more at 
the level of light microscopy in VPA group. 
We saw that there was almost no 
microvesicular steatosis in VPA+Vit E group. 
According to these results, it supports the idea 
mentioned in Buchi K.N. et al (1984) that the 
realising inhibition of LDH is due to Vit E and 
decreases the microvesicular steatosis at the 
rank of the light microscopy (3). 
When we compared the VPA + FA and 
VPA+E groups,we viewed that there was 
decrease of microvesicular steatosis in liver 
parenchyme in Vit E group, the swelling of 
Kuppfer cells was less and almost normal 
appearence, a decrease of mononuclear cell 
infiltration in artery, venule and connective 
tissue at periportal area as similar. As a result 
of these findings it was beleived that vitamin E 
has more protective effect when comparing 
with folic acid of preventing the liver 
hepatotoxicity according to folic acid.  
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